Ezetimibe/atorvastatin

DRUG3 trials

Sponsors

Organon and Co, Boryung Pharmaceutical Co., Ltd

Conditions

Essential HypertensionHypercholesterolemiaPrimary Hypercholesterolemia

Phase 3

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)

CompletedNCT01370590

Organon and CoHypercholesterolemia

Start: 2011-09-30End: 2012-04-30Updated: 2022-02-09

A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

CompletedNCT01370603

Organon and CoHypercholesterolemia

Start: 2011-09-30End: 2012-05-31Updated: 2022-02-09

A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

CompletedNCT05930028

Boryung Pharmaceutical Co., LtdEssential Hypertension, Primary Hypercholesterolemia

Start: 2023-07-13End: 2024-09-05Updated: 2024-10-18